About Palivizumab (Synagis) Dosing

This information provides clinical context for the Palivizumab (Synagis) Dose Calculator. Palivizumab is a humanized monoclonal antibody used for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients at high risk of RSV disease. Proper dosing is crucial for efficacy and safety.

Calculator Outputs Explained

The tool provides the following key outputs based on patient weight and the date of the first dose:

• Dose (mg): The total milligram dose of palivizumab, calculated at a standard rate of 15 mg/kg.
• Volume to Administer (mL): The precise volume for intramuscular injection, based on a standard concentration of 100 mg/mL.
• Vial Recommendation: A suggested combination of 50 mg and 100 mg vials to prepare the dose while minimizing drug wastage.
• Dosing Schedule: A five-dose administration schedule with dates set at approximately 30-day intervals, covering a typical RSV season.

How to Use the Calculator

To ensure accurate calculations, please enter the following information:

1. Patient Weight: Enter the most recent patient weight. You can input the value in either kilograms (kg) or pounds (lbs). The calculator will convert lbs to kg for the dose calculation.
2. Date of First Dose: Select the calendar date on which the first dose will be administered. This date serves as the starting point for generating the full 5-dose schedule.

Note: If a patient’s weight changes significantly between doses, a new dose should be calculated based on the current weight at the time of the subsequent administration.

Dosing Overview

The recommended dose of palivizumab is 15 mg per kg of body weight, given once a month by intramuscular (IM) injection. The first dose should be administered prior to the commencement of the RSV season, with subsequent doses given monthly throughout the season. A full course typically consists of five injections to provide protection for the duration of peak RSV activity.

Switching

Palivizumab has a specific indication and dosing schedule. It should not be used interchangeably with other RSV immunoprophylaxis agents, such as nirsevimab (Beyfortus), which has a different mechanism and dosing regimen. Any decision to switch or discontinue therapy should be based on updated clinical guidelines and individual patient assessment.

Missed Dose

If a scheduled dose of palivizumab is missed, the patient should receive the dose as soon as possible. The subsequent monthly dosing schedule should then be re-established from the date of this administration. Do not administer two doses at once to make up for a missed dose.

Safety Alerts

Palivizumab is generally well-tolerated. The most common adverse reactions are fever and rash. Serious adverse reactions are rare but can include:

• Hypersensitivity Reactions: Severe allergic reactions, including anaphylaxis and anaphylactic shock, have been reported. Palivizumab should only be administered in a healthcare setting where personnel and equipment are available to manage these events.
• Thrombocytopenia: Clinically significant bleeding or bruising may occur. Caution is advised in patients with bleeding disorders.

Refer to the full prescribing information for a complete list of warnings, precautions, and adverse events.

Frequently Asked Questions (FAQ)

Why does the calculator generate a 5-dose schedule?

A five-dose regimen is recommended by the American Academy of Pediatrics (AAP) to provide protection throughout a typical 5-month RSV season.

How does the tool select the recommended vials?

The calculator uses an algorithm to recommend a combination of 50 mg and 100 mg vials that meets the required dose while resulting in the least possible amount of medication waste.

What should I do if the patient’s weight changes during the season?

The dose of palivizumab for each monthly administration should be based on the patient’s current weight. You should use the calculator to recalculate the dose before each injection if there has been a significant weight change.

Can I use this calculator for nirsevimab (Beyfortus)?

No. This tool is specifically for palivizumab (Synagis). Nirsevimab has a different weight-based dosing structure and is administered as a single dose for the season.

What drug concentration does the calculator assume?

The calculator assumes a standard palivizumab concentration of 100 mg/mL for all volume calculations, as this is the concentration of the reconstituted or liquid product.

Why is the “Date of First Dose” input required?

This date is the anchor point for the tool to automatically generate a schedule of five subsequent monthly doses, helping with appointment planning.

Is the 30-day interval between doses strict?

The 30-day interval is an approximation for a monthly dose. Doses should be administered as close to monthly as is practical to maintain protective antibody levels.

Who is eligible to receive palivizumab?

Eligibility is determined by guidelines from bodies like the AAP. It typically includes infants born very prematurely, or those with certain chronic lung diseases or congenital heart conditions. The tool includes a summary of these criteria for reference.

References

1. SYNAGIS® (palivizumab) Prescribing Information. U.S. Food and Drug Administration. Accessed October 2023. View PDF
2. American Academy of Pediatrics. Updated Guidance: Use of Palivizumab Prophylaxis to Prevent Hospitalization From Severe Respiratory Syncytial Virus Infection During the 2021-2022 RSV Season. Accessed October 2023. aap.org
3. Centers for Disease Control and Prevention (CDC). Respiratory Syncytial Virus (RSV) Prevention for Infants and Young Children. Accessed October 2023. cdc.gov
4. Sobi North America. Synagis (palivizumab) for Healthcare Professionals. Accessed October 2023. synagis.com